<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00457587</url>
  </required_header>
  <id_info>
    <org_study_id>Wue-Immuno-ACC-83/05</org_study_id>
    <nct_id>NCT00457587</nct_id>
  </id_info>
  <brief_title>Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma</brief_title>
  <official_title>Präklinische Studie Zur Etablierung Einer Immuntherapie für Das Nebennierenrindenkarzinom - Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wuerzburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Krebshilfe e.V., Bonn (Germany)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wuerzburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis.&#xD;
      Surgical resection of the tumor is the treatment of choice. However, even after complete&#xD;
      resection more than 80 % of patients will experience recurrence of disease. Therefore, new&#xD;
      treatment options are urgently needed. This pre-clinical study try to lay the foundations for&#xD;
      a successful immunotherapy in patients with ACC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2005</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>To find reasonable antigens for a vaccination therapy in ACC</measure>
    <time_frame>day of blood sampling</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate the role of tumor-induced suppression in ACC</measure>
    <time_frame>NA, in vitro study</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Adrenocortical Carcinoma</condition>
  <condition>Cushing's Syndrome</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood for monocytes isolation serum urine tumor samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adrenocortical carcinoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with histological proven adrenocortical carcinoma&#xD;
&#xD;
          -  healthy persons as control group&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  autoimmune diseases&#xD;
&#xD;
          -  severe clinical condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Fassnacht, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wuerzburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Fassnacht, MD</last_name>
    <phone>49-931-201-36507</phone>
    <email>fassnacht_m@medizin.uni-wuerzburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sebastian Wortmann, MD</last_name>
    <email>wortmann_s@medizin.uni-wuerzburg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. of Medicine I, University of Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Fassnacht, MD</last_name>
      <phone>49-931-201-36507</phone>
      <email>fassnacht_m@medizin.uni-wuerzburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Silviu Sbiera, PhD</last_name>
      <email>sbiera_s@medizin.uni-wuerzburg.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.ukw.de/medizinische-klinik-i/endokrinologie/startseite/</url>
    <description>Homepage Dept. of Endocrinology, U Wuerzburg</description>
  </link>
  <results_reference>
    <citation>Landwehr LS, Altieri B, Schreiner J, Sbiera I, Weigand I, Kroiss M, Fassnacht M, Sbiera S. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. J Immunother Cancer. 2020 May;8(1). pii: e000469. doi: 10.1136/jitc-2019-000469.</citation>
    <PMID>32474412</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 4, 2007</study_first_submitted>
  <study_first_submitted_qc>April 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2007</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Wuerzburg</investigator_affiliation>
    <investigator_full_name>Martin Fassnacht</investigator_full_name>
    <investigator_title>Professor for Internal Medicine and Endocrinology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adrenocortical Carcinoma</mesh_term>
    <mesh_term>Cushing Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

